Adjuvante versus neoadjuvante Therapie beim Borderline-resektablen Pankreaskarzinom

[Article in German]

No authors listed

Comment

[Article in German]

No authors listed. Zentralbl Chir. 2018 Oct.

. 2018 Oct;143(5):457.

doi: 10.1055/a-0727-7234. Epub 2018 Oct 24.

No abstract available

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, Oh DY, Chie EK, Lee JM, Heo JS, Park JO, Lim DH, Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ, Choi SH. Jang JY, et al. Ann Surg. 2018 Aug;268(2):215-222. doi: 10.1097/SLA.0000000000002705. Ann Surg. 2018. PMID: 29462005 Clinical Trial.